Moderna (NASDAQ:MRNA) Stock Jumps 4.6% – What’s Next?

Moderna, Inc. (NASDAQ:MRNA)’s stock price shot up 4.6% during trading on Tuesday. The stock traded as high as $208.87 and last traded at $207.97. 17,511,972 shares traded hands during mid-day trading, an increase of 38% from the average daily volume of 12,691,296 shares. The stock had previously closed at $198.85.

Moderna News Roundup

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Investor enthusiasm is being driven by encouraging clinical data for Moderna’s personalized cancer vaccine, particularly in melanoma. CEO Stéphane Bancel said the results could improve with longer follow-up and argued that the company’s technology would be difficult for competitors to replicate. Moderna CEO cancer vaccine article
• Positive Sentiment: Coverage of Moderna’s presentation at the 2026 ESMO Congress has reinforced the view that oncology could become an important long-term growth engine and help diversify the company beyond COVID-19 products. Moderna ESMO presentation
• Neutral Sentiment: Investors are looking ahead to Moderna’s upcoming Nov. 6 update, which could provide additional information on the cancer program, commercial outlook and financial performance. Heavy online searches indicate elevated attention, but do not necessarily represent new fundamental buying. Moderna Nov. 6 outlook
• Negative Sentiment: William Blair lowered Moderna to Market Perform from Outperform, citing valuation concerns after the stock’s sharp rally. Analysts have also reduced their FY2028 EPS estimate, highlighting the risk that current expectations already price in substantial oncology success. William Blair Moderna rating downgrade
• Negative Sentiment: Comparisons with GSK emphasize Moderna’s premium valuation and ongoing execution risk. GSK’s specialty-medicines growth, broader pipeline and dividend may appear more attractive to investors seeking established cash generation rather than higher-risk oncology upside. GSK versus Moderna growth comparison

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on MRNA shares. Piper Sandler reiterated an “overweight” rating and issued a $230.00 price objective (up from $167.00) on shares of Moderna in a research report on Monday. JPMorgan Chase & Co. boosted their target price on Moderna from $40.00 to $77.00 and gave the stock an “underweight” rating in a research report on Friday, August 21st. Jefferies Financial Group restated a “hold” rating and issued a $150.00 target price (up from $60.00) on shares of Moderna in a research note on Wednesday, August 19th. Singular Research raised Moderna to a “hold” rating in a report on Wednesday, September 23rd. Finally, William Blair downgraded Moderna from an “outperform” rating to a “market perform” rating in a research report on Tuesday. Six research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have given a Sell rating to the stock. According to MarketBeat.com, Moderna currently has a consensus rating of “Hold” and an average target price of $107.10.

Moderna Trading Up 3.3%

The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The stock’s fifty day moving average price is $179.75 and its two-hundred day moving average price is $84.64. The company has a market capitalization of $88.31 billion, a PE ratio of -27.62 and a beta of 1.09.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The company had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. During the same quarter in the previous year, the business earned ($2.13) EPS. Moderna’s revenue was up 2.1% compared to the same quarter last year. Sell-side analysts anticipate that Moderna, Inc. will post -6.11 earnings per share for the current year.

Insider Buying and Selling at Moderna

In related news, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the sale, the insider directly owned 74,129 shares in the company, valued at $10,374,353.55. The trade was a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James M. Mock sold 34,836 shares of the business’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the sale, the chief financial officer owned 59,375 shares in the company, valued at approximately $7,985,343.75. This trade represents a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 197,251 shares of company stock valued at $33,875,904. 10.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Moderna

Several large investors have recently modified their holdings of MRNA. Western Pacific Wealth Management LP purchased a new position in shares of Moderna in the third quarter valued at approximately $29,000. Allied Private Wealth LLC acquired a new position in shares of Moderna in the second quarter valued at approximately $30,000. Canton Hathaway LLC purchased a new position in Moderna in the 1st quarter valued at approximately $31,000. Archer Investment Corp acquired a new position in shares of Moderna in the second quarter worth $36,000. Finally, Ramsey Quantitative Systems acquired a new position in shares of Moderna in the third quarter worth $40,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.